ArticleJournal of clinical medicine2020
A Pilot Study on MicroRNA Profile in Tear Fluid to Predict Response to Anti-VEGF Treatments for Diabetic Macular Edema.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Tear-fluid-derived biomarkers of ocular complications in diabetes: a systematic review and meta-analysis.BMC medicine · 2025Pooled it
- Emerging mechanisms in dry eye disease: apoptosis-associated tear MicroRNAs and toxicant-related alterations of the glycocalyx and lipid rafts.Frontiers in ophthalmology · 2026Article
- Review
- An Exploratory Analysis of Differential Tear Fluid miRNAs in Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes.Molecular neurobiology · 2025Article
- The role of peripheral blood microRNAs in the pathogenesis and treatment response of age-related macular degeneration.Future science OA · 2025Review
- Metabolomics analysis uncovers metabolic changes and remodeling of anti-VEGF therapy on macular edema.Eye and vision (London, England) · 2025Article
- Non-invasive miRNAs for early detection and diagnosis of lacrimal adenoid cystic carcinoma.Discover oncology · 2024Article
- Tear Film MicroRNAs as Potential Biomarkers: A Review.International journal of molecular sciences · 2023Review
- Novel RNA extraction method from human tears.Molecular biology research communications · 2022Article
- Potential utility of miRNAs for liquid biopsy in breast cancer.Frontiers in oncology · 2022Review
- Tear miRNA expression analysis reveals miR-203 as a potential regulator of corneal epithelial cells.BMC ophthalmology · 2021Article
- Expression of microRNA-155-5p in patients with refractory diabetic macular edema and its regulatory mechanism.Experimental and therapeutic medicine · 2021Article
- Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy.International journal of molecular sciences · 2021Review
- Serum exosomal miR-377-3p inhibits retinal pigment epithelium proliferation and offers a biomarker for diabetic macular edema.The Journal of international medical research · 2021Article
- miR-98 Regulates TMPRSS2 Expression in Human Endothelial Cells: Key Implications for COVID-19.Biomedicines · 2020Article
- Role of Systemic Factors in Improving the Prognosis of Diabetic Retinal Disease and Predicting Response to Diabetic Retinopathy Treatment.Ophthalmology scienceReview
- Machine learning uncovers novel sex-specific dementia biomarkers linked to autism and eye diseases.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
Abstract
(1) Background: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) is an established treatment for center-involving diabetic macular edema (ci-DME). However, the clinical response is heterogeneous. This study investigated miRNAs as a biomarker to predict treatment response to anti-VEGF in DME. (2) Methods: Tear fluid, aqueous, and blood were collected from patients with treatment-naïve DME for miRNA expression profiling with quantitative polymerase chain reaction. Differentially expressed miRNAs between good and poor responders were identified from tear fluid. Bioinformatics analysis with the miEAA tool, miRTarBase Annotations, Gene Ontology categories, KEGG, and miRWalk pathways identified interactions between enriched miRNAs and biological pathways. (3) Results: Of 24 participants, 28 eyes received bevacizumab (15 eyes) or aflibercept (13 eyes). Tear fluid had the most detectable miRNA species (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.